AKT2 and cancer: We enrolled a total of twelve patients across eight different cancer types, including six patients with non-AKT1 E17K mutations (AKT1 D323G, E40K, L52R; AKT2 E17K, L78-Q79ins(HANTFVIRCL); AKT3 E17K) in this signal-seeking pilot study (Supplementary Fig. 10a and Supplementary Table 3).